The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.
While Health Technology Assessment agencies anticipate that joint efforts and harmonisation will enhance evaluations’ ...
A new global guideline for the diagnosis and treatment of Candida infections was recently published in Lancet Infectious ...
A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most ...
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...
MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...
The global sugar market is expected to produce 186.6 million tons in 2025, an increase of 2.8 million tons from the previous year, but  the USDA forecasts a 4.7% year-over-year decline in global sugar ...
DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...
Hyderabad: Aurobindo Pharma has announced that the European Commission (EC) has granted marketing authorization in the ...
Biologics Ltd (BBL), a subsidiary of Biocon Limited, has secured a major regulatory milestone with the European Commission ...